RxDoctor Payments Data

Joseph Blackburn, MD

Family Medicine · Medina, OHNPI 1730183138

Payments from drug & device makers

$12,035in general payments, 2019–2025

Across 784 payments — averaging $15.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$2K
  • Pfizer$1K
  • Lilly USA, LLC$921
  • Astellas Pharma US Inc$621
  • Novo Nordisk$527
  • plus $5K from 50 others

What the payments were for

  • Food & beverage$11,86399%
  • Education$1721%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,035 in reported general payments places this provider in the 95th percentile of 3,983 family medicine providers in Ohio.

See all family medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$121,962
Medicare patients
370
Services billed
1,754

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban229$184,990
OzempicSemaglutide55$66,201
FarxigaDapagliflozin Propanediol43$50,266
JardianceEmpagliflozin28$38,094
JanuviaSitagliptin Phosphate21$31,889
XareltoRivaroxaban40$28,757
TrulicityDulaglutide20$21,389
JanumetSitagliptin Phos/Metformin Hcl19$17,587
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$16,990
MyrbetriqMirabegron23$12,482
TradjentaLinagliptin14$10,409
Lantus SolostarInsulin Glargine,hum.Rec.Anlog39$6,501
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$5,055
Atorvastatin Calcium528$4,986
Breo ElliptaFluticasone/Vilanterol13$4,729

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,054$184,990229 claims
Novo NordiskOzempic$527$66,20155 claims
AstraZenecaFarxiga, Symbicort$1,780$53,77657 claims
MerckJanuvia, Janumet$261$49,47640 claims
Boehringer IngelheimJardiance, Tradjenta$182$48,50342 claims
Johnson & JohnsonXarelto$284$28,75740 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$467$26,77450 claims
Lilly USA, LLCTrulicity$921$21,38920 claims
Astellas Pharma US IncMyrbetriq$621$12,48223 claims
AbbVieSynthroid$1,790$3,668112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,983 family medicine providers in Ohio.

Other family medicine in Medina

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →